Thelansis

 Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS), characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. Lesions in the CNS can manifest at different times and locations, leading to the description of MS lesions as being "disseminated in time and space." The clinical course of MS varies widely, ranging from a stable chronic illness to a rapidly progressing and debilitating condition. Approximately 70 to 80% of MS patients experience an initial onset marked by a relapsing-remitting (RR) course, while 15 to 20% present with primary progressive (PP) MS, characterized by gradual deterioration without relapses. Secondary progressive (SP) MS, affecting a subset of patients after an initial RR course, involves a more gradual neurological decline. Diagnosis of RR MS requires evidence of at least two CNS inflammatory events, with relapses often showing partial or complete recovery over weeks to months, frequently w...

 Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS), characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. Lesions in the CNS can manifest at different times and locations, leading to the description of MS lesions as being "disseminated in time and space." The clinical course of MS varies widely, ranging from a stable chronic illness to a rapidly progressing and debilitating condition. Approximately 70 to 80% of MS patients experience an initial onset marked by a relapsing-remitting (RR) course, while 15 to 20% present with primary progressive (PP) MS, characterized by gradual deterioration without relapses. Secondary progressive (SP) MS, affecting a subset of patients after an initial RR course, involves a more gradual neurological decline. Diagnosis of RR MS requires evidence of at least two CNS inflammatory events, with relapses often showing partial or complete recovery over weeks to months, frequently w...

  Multiple Sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. Lesions in the CNS occur at different times and in other CNS locations. Because of this, multiple sclerosis lesions are sometimes said to be "disseminated in time and space." The clinical course of the disease is quite variable, ranging from stable chronic illness to a rapidly evolving and debilitating condition. 70 to 80% of MS patients demonstrate an initial onset characterized by a relapsing-remitting (RR) course, Primary progressive (PP), 15 to 20% of patients present with a gradual deterioration from the start, with an absence of relapses, Secondary progressive (SP) characterized by a more gradual neurologic decline after an initial RR course. The course may be relapsing-remitting or progressive. The diagnosis of RR MS is made with at least two CNS inflammatory events. Relapses often recover partially or entirely...